Basics Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). IPO Date: February 6, 2007 Sector: Healthcare Industry: Biotech Market Cap: $9.58B Activated in VL: True Average Daily Range Avg Daily Range: $3.67 | 2.57% Avg Daily Range (30 D): $6.35 | 1.46% Avg Daily Range (90 D): $6.77 | 1.86% Institutional Daily Volume Avg Daily Volume: .21M Avg Daily Volume (30 D): .2M Avg Daily Volume (90 D): .27M Trade Size Avg Trade Size (Sh.): 44 Avg Trade Size (Sh.) (30 D): 26 Avg Trade Size (Sh.) (90 D): 29 Institutional Trades Total Inst.Trades: 2,341 Avg Inst. Trade: $6.1M Avg Inst. Trade (30 D): $17.23M Avg Inst. Trade (90 D): $13.62M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $6.54M Avg Closing Trade (30 D): $18.81M Avg Closing Trade (90 D): $15.6M Avg Closing Volume: 32.73K     News Sep 10, 2025 @ 1:27 PM CoreWeave and Madrigal’s Insider Trades Fla... Source: Leo Miller Aug 5, 2025 @ 8:07 PM Madrigal (MDGL) Q2 Revenue Soars 1,313% Source: Na Jul 25, 2025 @ 12:00 PM Madrigal Pharmaceuticals to Release Second-Quarter... Source: Madrigal Pharmaceuticals May 10, 2025 @ 11:15 AM Madrigal Announces New Clinical Data Demonstrating... Source: N/A Apr 18, 2025 @ 12:00 PM Madrigal Pharmaceuticals to Release First-Quarter ... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.9 $-3.32 $-2.59 Diluted EPS $-1.9 $-3.32 $-2.59 Revenue $ 212.8M $ 137.25M $ 103.32M Gross Profit $ $ 132.74M $ Net Income / Loss $ -42.28M $ -73.24M $ -59.42M Operating Income / Loss $ -47.2M $ -79.31M $ -67M Cost of Revenue $ $ 4.51M $ Net Cash Flow $ 2.55M $ 83.63M $ -132.67M PE Ratio     Splits Jul 25, 2016:   1:35